At the American Academy of Orthopaedic Surgeons Annual Meeting, Cayenne Medical Inc. announced the launch of its BioWick platform technology.
According to a company press release, the first solution to use this technology seeks to address the biology issue correlated with rotator cuff repair failures. The BioWick SureLock Implant is an interpositional scaffold wick that is deployed arthroscopically between the tendon and the bone. The implant reportedly reduces bone removal by way of a smaller pilot hole and allows orthopedic surgeons to continue with their current standard techniques.
“The BioWick platform is a continuation of Cayenne Medical’s philosophy of innovation to address significant unmet clinical needs while saving procedure time and being cost effective,” Dave Springer, president and chief executive officer of Cayenne Medical, said in the release. “We believe our differentiated design supported by statistically significant animal data will provide the most integrated approach in addressing the large failure rate with initial rotator cuff repairs.”
According to the release, the implant is made of aligned poly (lactic-co-glycolic) acid microfibers in order to mimic the extracellular matrix of the rotator cuff tendon. Cayenne Medical received 510(k) FDA clearance for the BioWick SureLock Implant in July of 2015.